Vise Technologies Inc. Takes Position in Ascendis Pharma A/S $ASND

Vise Technologies Inc. bought a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the 2nd quarter, HoldingsChannel reports. The fund bought 1,284 shares of the biotechnology company’s stock, valued at approximately $222,000.

Other institutional investors and hedge funds have also modified their holdings of the company. T. Rowe Price Investment Management Inc. lifted its stake in Ascendis Pharma A/S by 12.0% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock worth $475,970,000 after acquiring an additional 328,278 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at about $51,029,000. RA Capital Management L.P. lifted its position in shares of Ascendis Pharma A/S by 1.7% in the first quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock worth $1,602,474,000 after purchasing an additional 168,752 shares in the last quarter. Braidwell LP purchased a new stake in shares of Ascendis Pharma A/S in the first quarter worth approximately $16,632,000. Finally, Driehaus Capital Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 71.6% during the first quarter. Driehaus Capital Management LLC now owns 151,829 shares of the biotechnology company’s stock worth $23,664,000 after purchasing an additional 63,333 shares during the period.

Ascendis Pharma A/S Trading Up 5.9%

ASND stock opened at $216.56 on Tuesday. The firm has a market cap of $13.36 billion, a PE ratio of -41.97 and a beta of 0.44. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $223.19. The company has a fifty day simple moving average of $202.09 and a 200 day simple moving average of $185.16.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, November 12th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The business had revenue of $290.24 million for the quarter, compared to analysts’ expectations of $246.91 million. As a group, analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on ASND. Wells Fargo & Company reiterated an “overweight” rating and issued a $295.00 price objective (up previously from $289.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. UBS Group reiterated a “buy” rating and set a $307.00 price objective (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, October 8th. Finally, Wedbush upped their target price on Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.71.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.